OMER

Omeros Stock Price

15.15
0.00 (0.0%)
15.15
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Omeros Corporation OMER NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 15.15 0.00 0.00 0.00 15.15 09:20:28
Bid Price Ask Price Spread Spread % News
15.12 16.03 0.91 5.68% - -
Stock Trades Traded Volume Average Volume 52 Week Range
1 2 402,506 8.50 - 20.92
Last Trade Time Type Quantity Stock Price Currency
08:58:12 2 $ 15.15 USD

Omeros Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 825.84M 54.51M 51.80M $ 111.80M $ -96.38M -1.71 -8.57
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Omeros News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OMER Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week14.8215.364314.1414.85491,4200.332.23%
1 Month14.7316.1414.1415.04459,9340.422.85%
3 Months13.5417.2113.1415.22465,2691.6111.89%
6 Months13.2120.608.5014.56630,6571.9414.69%
1 Year14.6720.928.5015.05539,7540.483.27%
3 Years20.0927.008.3616.42723,745-4.94-24.59%
5 Years17.0030.257.2015.99685,969-1.85-10.88%

Omeros Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.